Alkermes released FY2025 Q2 earnings on July 29 During-Market (EST), actual revenue USD 390.66 M (forecast USD 341.24 M), actual EPS USD 0.52 (forecast USD 0.2345)

Brief Summary

Alkermes reported Q2 2025 earnings with a revenue of $390.7 million and an EPS of $0.52, significantly exceeding market expectations of $341 million in revenue and $0.2345 in EPS.

Impact of The News

The financial performance of Alkermes in Q2 2025 has been notably strong, surpassing market analysts’ expectations. The company’s revenue of $390.7 million and EPS of $0.52 exceeded the anticipated figures of $341 million and $0.2345 respectively Reuters+ 2. This robust performance is primarily attributed to strong sales of its proprietary products, with Lybalvi’s revenue reaching $84.3 million, up 18% from the prior year, and Aristada’s revenue hitting $101.3 million, also up 18% year-over-year Reuters. Despite a decline in total six-month revenue compared to the previous year due to decreased manufacturing and royalty revenue, the quarterly performance highlights the strength of Alkermes’ core products TradingView.

The positive earnings report suggests a strong business outlook for Alkermes, reinforcing confidence in its financial stability and growth potential. The company’s reaffirmation of its 2025 financial expectations, as initially set in February, further underscores a positive trajectory Reuters. Considering the favorable market reaction to the earnings beat, investors might anticipate continued strong performance and potential stock price appreciation in the near term. This financial disclosure also enhances Alkermes’ competitive position among peer pharmaceutical companies, showcasing its ability to deliver solid financial results amidst a challenging market environment.